LATEEF KELANI: Open Payments
NPI 1164028189 · LISLE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$715 in 32 payments from 10 companies in 2025. Trend: 2023 $376 · 2024 $560 · 2025 $715
Food & beverage: $715
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $221 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Neurocrine BioSciences, Inc. | 4 | $83 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $60 |
| Lundbeck LLC | 2 | $48 |
| Alkermes, Inc. | 1 | $31 |
| Tris Pharma Inc | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: VRAYLAR, REXULTI, INGREZZA, Auvelity, UZEDY, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across IL — which companies pay providers there.
